Brought to you by:
SCVS 2022: WIfI score does not predict successful healing after transmetatarsal amputation, study finds
A higher initial Wound, ischemia, and foot infection (WIfI) classification score at initial presentation in chronic limb-threatening ischemia (CLTI) patients who underwent a transmetatarsal amputation (TMA) was not associated with a major amputation down the road, according to a retrospective…
Potential ‘new paradigm’ in treatment of long occlusive lesions emerges
Vascular surgeon Lewis Schwartz, MD, has had an interest in biomedical engineering since very early in his career. So his involvement in the early-stage Efemoral vascular scaffold system marks a significant milestone in a mission to save legs and provide…
PROMISE II U.S. pivotal trial of device designed for ‘no-option’ CLTI patients completes enrollment
Enrollment has been completed in the PROMISE II pivotal trial of the LimFlow deep vein arterialization system designed to prevent amputations in so-called “no-option” chronic limb-threatening ischemia (CLTI) patients, the eponymous device maker announced today. “The PROMISE II investigators are…
Viabahn use in claudicants with long, complex SFA lesions ‘safe and effective’ through five years
Recently published research indicates that stent grafting with the Viabahn endoprosthesis (W L Gore & Associates) of long and complex superficial femoral artery (SFA) lesions in patients with claudication is a safe and effective long-term treatment option. Writing in the Journal of Vascular…
Ra Medical Systems receives FDA approval for increased enrollment in atherectomy clinical trial
Ra Medical Systems, a medical device company focused on developing the excimer laser system to treat vascular diseases, has announced that enrollment has reached 95 subjects in the pivotal clinical trial to evaluate the safety and effectiveness of the DABRA…
The top 10 most popular Vascular Specialist stories in January
January’s top 10 includes “Our forever plague,” a combined editorial by Malachi Sheahan III, MD, our medical editor, on fake news and science, and coverage of the U.S. investigational device exemption (IDE) Aortic Research Consortium and how the chief investigators…
Index atherectomy interventions for claudication ‘is associated with higher’ reintervention rates vs. other technologies
Atherectomy use during index peripheral vascular interventions in claudicants is associated with higher reintervention rates when compared to other technologies, a newly unveiled study by Caitlin Hicks, MD, and colleagues at Johns Hopkins Hospital in Baltimore, Maryland, shows. The researchers…
Cook Medical receives FDA breakthrough designation for new drug-eluting stent
Cook Medical has received Breakthrough Device designation from the Food and Drug Administration (FDA) on a new drug-eluting stent (DES) for below the knee (BTK). This new stent is designed to treat patients suffering from chronic limb-threatening ischemia (CLTI). The Breakthrough…
ISET 2022 audience hears latest data on endovascular therapies
At this year’s International Symposium on Endovascular Therapy (ISET), being held Jan. 16–19 in Hollywood, Florida, experts presented an array of late-breaking trial results on topics ranging from venous stenting to abdominal aortic aneurysm (AAA) sac sealing. Waseem Wahood, MS, a…
CSI announces development of IVL technology for the treatment of PAD
Cardiovascular Systems (CSI) recently announced that it has made significant progress towards the commercialization of its intravascular lithotripsy (IVL) system for the treatment of calcific peripheral arterial disease (PAD). A company press release notes that feasibility testing of a proprietary…